# Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP

> **NCT01107951** · PHASE2 · COMPLETED · sponsor: **Hospital Universitario Dr. Jose E. Gonzalez** · enrollment: 21 (actual)

## Conditions studied

- Immune Thrombocytopenic Purpura

## Interventions

- **DRUG:** Rituximab and dexamethasone

## Key facts

- **NCT ID:** NCT01107951
- **Lead sponsor:** Hospital Universitario Dr. Jose E. Gonzalez
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2010-04
- **Final completion:** 2013-01
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2013-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01107951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01107951, "Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT01107951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*